Search results
PROMOTED
Stay up to date with the latest clinical evidence in transthyretin amyloid cardiomyopathy (ATTR-CM) with this video series spotlighting key cardiomyopathy updates presented at ESC Heart Failure Congress (HFA) 2026.In the first session, Dr Mathew Maurer (Columbia University, New York, US) takes a deep dive into the CARDIO-TTRansform data, exploring the current treatment landscape and ongoing unmet…
View more
Spotlight on HFA 2026: Updates on Cardiomyopathies
Added:
1 month ago
Video Series
Added:
10 months ago
Added:
2 months ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,…
View more
Added:
6 days ago
Dr Lin Yee Chen (University of Minnesota Medical School, Minneapolis, MN, US) joins us to examine which artificial intelligence (AI) applications in heart failure are ready for clinical use today, and which remain experimental. As AI moves from research settings into the clinic, separating genuine clinical utility from hype has become a pressing question for heart failure specialists.In this…
View more
Benefits of Spironolactone: Win Ratio Analysis of the TOPCAT Trial
Added:
8 months ago
Original Research
PAP Therapies for HF: What Do the Trials Tell Us?
Added:
6 months ago
Review Article
Added:
2 months ago
ACC.26 - Dr Anuradha Lala-Trindade (Mount Sinai, New York, NY, US) provides her expert analysis of the most impactful late-breaking clinical trials presented at ACC.26, highlighting studies with the potential to influence clinical practice and shape future cardiovascular care. Key Late-Breaking Trials Discussed0:16 – STEMI-DTU: Primary Left Ventricular Unloading in Anterior ST-Segment Elevation…
View more
Lipoprotein(a): A Risk Factor and Biomarker in Heart Failure
Added:
1 month ago
Review Article
Reverse Remodelling in HFrEF
Added:
6 months ago
Review Article
Added:
9 months ago
Source:
Radcliffe Cardiology
Results from the Phase III VICTOR trial, presented at the European Society of Cardiology (ESC) Congress 2025 and published in The Lancet, show that vericiguat did not meet its primary endpoint in patients with chronic, stable heart failure with reduced ejection fraction (HFrEF).¹˒²Vericiguat is an oral, once-daily stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide…
View more